Earnings Call · Q4 FY2024·2025-03-17

Q4 24EPS -21.01%·Rev n/aQ3 24EPS +100.00%*·Rev n/aQ2 24EPS -6.25%·Rev n/aQ1 24EPS -4.17%·Rev n/a⚠ consensus missing

SANGAMO THERAPEUTICS, INC SGMO

Louise Wilkie — Investor Relations or Communications

Sandy Macrae — Chief Executive Officer

Nathalie Dubois-Stringfellow — Chief Development Officer

−16.2%1d on move date−15.1% vs SPY3d−16.9%5d−13.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SGMO calls or request research access.

More SGMO calls Browse calls Request research access